Other pathways are being investigated as potential targets for CML, including immune signaling [105, 106] and the JAK/STAT [110–112] and mTOR [98, 121] pathways. This evidence concerns the gene SOAT1 and chronic myelogenous leukemia, BCR-ABL1 positive.